Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

BioMarin: EPS Surges Past Expectations

TheMotleyFool

0 0

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated $0.53. Revenue in Q4 hit $747 million, exceeding the estimated $712 million and rising 16% year over year.

The quarter was marked by strong financial performance, underpinned by strategic expansions in its product lines.

Source: BioMarin Pharmaceutical. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.

Source Fool.com